RIPRINT – the end of the Reprint, as we know it…
Reprints help pharma companies provide the clinical evidence behind their marketing claims, which the majority of doctors insist on seeing, rather than relying on a pharma company’s own marketing materials. Yet reprint volume has seen steady decline in the last decade and the majority of reprints are still delivered as hard copies rather than digitally. We asked Philip Ditchfield, information specialist, who has worked for some of the world’s largest publishers and also on the reprint buying side for big pharma – why there has been a decline in recent years, and what the future is for digital ePrints.
This white paper, commissioned by Tangent 90, answers those questions and explores:
- reprints and the medical market
- the reprint lifecycle and transition to ePrints
- an alternative pricing model that works for all stakeholders
- a reprint buyer’s checklist